DE69216888T2 - The equatorially linked beta 1-4 polyuronates and their use to stimulate the cytokines - Google Patents

The equatorially linked beta 1-4 polyuronates and their use to stimulate the cytokines

Info

Publication number
DE69216888T2
DE69216888T2 DE69216888T DE69216888T DE69216888T2 DE 69216888 T2 DE69216888 T2 DE 69216888T2 DE 69216888 T DE69216888 T DE 69216888T DE 69216888 T DE69216888 T DE 69216888T DE 69216888 T2 DE69216888 T2 DE 69216888T2
Authority
DE
Germany
Prior art keywords
cytokines
polysaccharides
present
monocytes
chitosan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69216888T
Other languages
German (de)
Other versions
DE69216888D1 (en
Inventor
Marit Otterlei
Terje Espevik
Gudmund Skjak-Braek
Olav Smidsrod
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOBIPOL NOBIPOLS FORSKNINGSSTI
Pronova Biopolymer AS
Original Assignee
NOBIPOL NOBIPOLS FORSKNINGSSTI
Pronova Biopolymer AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NOBIPOL NOBIPOLS FORSKNINGSSTI, Pronova Biopolymer AS filed Critical NOBIPOL NOBIPOLS FORSKNINGSSTI
Application granted granted Critical
Publication of DE69216888D1 publication Critical patent/DE69216888D1/en
Publication of DE69216888T2 publication Critical patent/DE69216888T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

The present invention is directed to a material and method for the stimulation of the production of cytokines. Several polysaccharides, including polymers of different size of beta 1-4 linked D-mannuronic acid (poly-M and M-blocks), chitosan and cellulose oxidized in C-6 position (C60XY) induce human monocytes to produce the cytokines. Preferably, the molecular weights of poly-M and chitosan are above 50,000 and 20,000 respectively. Pretreatment of the monocytes with IFN- gamma increases the cytokine production from monocytes stimulated with all polysaccharides tested. The subject polysaccharides worked in vivo and in vitro. The present invention has therapeutic utility as vaccine adjuvants and components. Therapeutic compositions comprising biologically active quantities of the compositions of the present invention may be employed to potentiate antibody production in response to vaccine antigens. Anti-tumor, anti-bacteriological, anti-fungal and anti-viral effects may be expected.
DE69216888T 1991-03-27 1992-03-24 The equatorially linked beta 1-4 polyuronates and their use to stimulate the cytokines Expired - Lifetime DE69216888T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/676,103 US5169840A (en) 1991-03-27 1991-03-27 Diequatorially bound β-1, 4 polyuronates and use of same for cytokine stimulation

Publications (2)

Publication Number Publication Date
DE69216888D1 DE69216888D1 (en) 1997-03-06
DE69216888T2 true DE69216888T2 (en) 1997-06-12

Family

ID=24713242

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69216888T Expired - Lifetime DE69216888T2 (en) 1991-03-27 1992-03-24 The equatorially linked beta 1-4 polyuronates and their use to stimulate the cytokines

Country Status (6)

Country Link
US (1) US5169840A (en)
EP (1) EP0506326B1 (en)
JP (1) JP3523654B2 (en)
AT (1) ATE147984T1 (en)
DE (1) DE69216888T2 (en)
DK (1) DK0506326T3 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE241984T1 (en) * 1993-03-26 2003-06-15 Franciscus Wilhelmus He Merkus PHARMACEUTICAL COMPOSITIONS FOR INTRANASAL ADMINISTRATION OF APOMORPHINE
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
GB9522351D0 (en) * 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
NO305033B1 (en) * 1997-05-09 1999-03-22 Algipharma As Process for the preparation of uric acid blocks from alginate
GB2325233B (en) * 1997-05-16 2001-07-18 Norsk Hydro As Substrates having bound polysaccharides and bacterial nucleic acids
IL135148A0 (en) * 1997-10-03 2001-05-20 Galenica Pharmaceuticals Inc A polysaccharide conjugate and pharmaceutical compositions containing the same
AU760669B2 (en) 1998-04-28 2003-05-22 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
FR2781673B1 (en) * 1998-07-28 2001-09-28 Univ Picardie USE OF A GLUCURONANE AS AN IMMUNOSTIMULATING AGENT, METHOD OF PREPARATION
KR100501584B1 (en) * 2000-02-03 2005-07-18 (주)케이비피 Process for preparing low molecular polymannuronate, a novel use thereof as controller of serum lipids, and functional foods and health-aid foods comprising the same
NO320671B1 (en) * 2001-11-30 2006-01-16 Fmc Biopolymer As Method of stimulating weight gain in fish.
NO326145B1 (en) * 2001-11-30 2008-10-06 Fmc Biopolymer As Method of stimulating weight gain in mammals, birds and reptiles.
WO2005122739A2 (en) * 2004-06-15 2005-12-29 The New York Blood Center, Inc. Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus
CA2581330A1 (en) * 2004-09-21 2006-03-30 The Brigham And Women's Hospital, Inc. Methods and compositions relating to mannuronic acid specific binding peptides
WO2007069468A1 (en) * 2005-12-14 2007-06-21 Nagasaki University Cytokine secretion promoter
JP5109266B2 (en) * 2006-03-01 2012-12-26 凸版印刷株式会社 Antibacterial antifungal agent
CN104189908B (en) 2007-11-27 2017-01-11 阿尔吉法玛公司 Product comprising alginate oligomer, product comprising abiotic surface and composition for disinfection and cleaning
JP5202764B2 (en) 2009-06-03 2013-06-05 アルギファルマ エーエス Alginate oligomers used to overcome multidrug resistance in bacteria
GB0909529D0 (en) 2009-06-03 2009-07-15 Algipharma Ipr As Alginate oligomers for the inhibition of microbial adherence to surfaces
GB0909557D0 (en) 2009-06-03 2009-07-15 Algipharma Ipr As Anti-microbial alginate oligomers
GB201116010D0 (en) 2011-09-15 2011-10-26 Algipharma As Use of alginate oligomers to enhance the effects of antifungal agents
GB201504878D0 (en) 2015-03-23 2015-05-06 Algipharma As Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
GB201517639D0 (en) 2015-10-06 2015-11-18 Algipharma As Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU430857A1 (en) * 1970-05-18 1974-06-05 Харьковский научно исследовательский институт общей , неотложной хирургии , Харьковский нау исследовательский химико фармацевтический институт Blood Circulatory Drug
US4605623A (en) * 1982-11-08 1986-08-12 Malette William Graham Method of altering growth and development and suppressing contamination microorganisms in cell or tissue culture
US4578458A (en) * 1983-03-23 1986-03-25 Brigham And Women's Hospital Mucoid exopolysaccharide vaccine against Pseudomonas aeruginosa
JPS6164701A (en) * 1984-09-06 1986-04-03 Meito Sangyo Kk Cationized dextran derivative/polyuronic acid polyelectrolyte complex and its use
EP0240098A3 (en) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
JP2527317B2 (en) * 1986-12-19 1996-08-21 ライオン株式会社 Bone disease treatment
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
US5002759A (en) * 1989-07-25 1991-03-26 Colgate-Palmolive Company Oligosaccharide inhibition of Streptococcus pyogenes adhesion

Also Published As

Publication number Publication date
EP0506326B1 (en) 1997-01-22
DE69216888D1 (en) 1997-03-06
ATE147984T1 (en) 1997-02-15
JPH0687751A (en) 1994-03-29
DK0506326T3 (en) 1997-07-14
US5169840A (en) 1992-12-08
EP0506326A3 (en) 1992-12-30
EP0506326A2 (en) 1992-09-30
JP3523654B2 (en) 2004-04-26

Similar Documents

Publication Publication Date Title
DE69216888D1 (en) The equatorially linked beta 1-4 polyuronates and their use to stimulate the cytokines
DE60035487T2 (en) TREATMENT OF DENDRITIC CELLS WITH IMMUNE RESPONSE MODIFYING COMPOUNDS
BR9307104A (en) Reinforcing preparations of host and migrant defense mechanisms with single peak water-soluble b-glycan methods to produce a reinforcing preparation of host defense meanisms to prevent infection in a mammal to stimulate wound repair and healing and to stimulate the proliferation of platelets pharmaceutical composition and method for treating infection in mammals
DE69533941T2 (en) METHOD FOR THE PRODUCTION OF A MEDICAMENT FOR TREATING THE SECONDARY IMMUNE
Luty et al. Subacute toxicity of orally applied alpha-cypermethrin in Swiss mice
YU47543B (en) PROCEDURE FOR OBTAINING PHARMACEUTICAL PREPARATION FOR GRANULLocyte Stimulation
CA2167090A1 (en) Compositions and methods for stimulating megakaryocyte growth and differentiation
US5108745B1 (en) Tuberculosis and legionellosis vaccines and methods for their production
DE3877492D1 (en) PHARMACEUTICAL PREPARATION WITH DELAYED DELIVERY OF A DIHYDROPYRIDINE AND A BETA ADRENO RECEPTOR ANTAGONIST AND PRODUCTION METHOD THEREOF.
DK66692A (en) A MAMMAL CYTOKIN, IL-11
Wang et al. In vivo and in vitro cocaine modulation on production of cytokines in C57BL/6 mice
IL85476A (en) Sustained release polysaccharide bound compositions for parenteral administration and their use in animals
ES2017008B3 (en) FUNDIBLE PALLADIUM ALLOYS AND THEIR FOLDING TO MAKE ORNATES, DENTAL AND SIMILAR RESTORATIONS.
Coleman et al. Interferon‐γ inhibits serotonin release from mouse peritoneal mast cells
EP0593625A4 (en) Short-term anti-cd3 stimulation of lymphocytes to increase their in vivo activity.
Schwartz et al. Enhanced hematopoietic recovery in irradiated mice pretreated with interleukin-1 (IL-1)
ATE86489T1 (en) AID-FREE RIBOFLAVING GRANULES.
IT1231126B (en) PROCEDURE FOR THE PRODUCTION OF ARTIFICIAL VENEERING BY IMITATION OF BRIAR, BY BURNS.
Dy et al. Skin allografts generate an enhanced production of histamine and histamine-producing cell-stimulating factor (HCSF) by spleen cells in response to T cell mitogens.
Emmendörffer et al. Immunologically active polysaccharides from Echinacea purpurea plant and cell cultures
Valenzona et al. Exogenous interleukin 7 as a proliferative stimulant of early precursor B cells in mouse bone marrow: efficacy of IL-7 injection, IL-7 infusion and IL-7–anti-IL-7 antibody complexes
JPH08512326A (en) Pharmaceutical composition for immunomodulation and reinforcement treatment
Mosmann et al. Heterogeneity of mouse helper T cells and cross-regulation of TH1 and TH2 clones
Schackert et al. Activation of Monocytes and Lymphocytes by In Vitro Transfer and Expression of the Human Interleukin-2 Gene (hIL-2) in Human Tumor Cells
Stingl Immunorgan Epidermis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition